Avigen Inc., an Alameda, Calif., biotechnology company, said the U.S. Food and Drug Administration has approved a second clinical trial in humans of its gene-therapy treatment for hemophilia B.

Gene therapy, in which doctors attempt to replace malfunctioning genes with healthy versions via genetic manipulation, is a tricky process that so far has yielded mixed results. Avigen's process involves the use of a virus called...